Company Overview
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Key Highlights
- Biotechnology · Healthcare
- Led by Stephen H. Willard
- 38 employees
- Based in Miami, FL
Price History
Loading…
Data from Twelve Data. Prices may be delayed.
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Nov 12
Initial Jobless Claims
8:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
73,785 −1.58%
Ethereum (ETH)
2,055 −3.30%
Solana (SOL)
83 −3.55%
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Miami, FL, US
- Incorporated
- Feb 12, 2021
- Website
- www.longeveron.com
Latest SEC Filings
View All Filings →- Current Report (Form 8-K)Nov 5, 2026